Breast cancer is the most common cancer in women worldwide. To address this issue, Guardant Health AMEA has increased access of the Guardant360® test to 41 countries in Asia, Middle East and Africa. Our FDA-approved liquid biopsy can find actionable mutations in advanced cancer patients within 7 days from sample receipt in the laboratory, helping patients to access appropriate treatment quickly and safely.

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

https://lnkd.in/gEmdiwt

Guardant360®. Test. Take Action.